DE60142237D1 - Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen - Google Patents
Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständenInfo
- Publication number
- DE60142237D1 DE60142237D1 DE60142237T DE60142237T DE60142237D1 DE 60142237 D1 DE60142237 D1 DE 60142237D1 DE 60142237 T DE60142237 T DE 60142237T DE 60142237 T DE60142237 T DE 60142237T DE 60142237 D1 DE60142237 D1 DE 60142237D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- agents
- cronically
- autoimmun
- flammable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22407900P | 2000-08-08 | 2000-08-08 | |
PCT/US2001/024783 WO2002011767A2 (en) | 2000-08-08 | 2001-08-06 | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60142237D1 true DE60142237D1 (de) | 2010-07-08 |
Family
ID=22839207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142237T Expired - Lifetime DE60142237D1 (de) | 2000-08-08 | 2001-08-06 | Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen |
Country Status (10)
Country | Link |
---|---|
US (5) | US6652854B2 (de) |
EP (1) | EP1307225B1 (de) |
JP (1) | JP4938957B2 (de) |
AT (1) | ATE468860T1 (de) |
AU (2) | AU2001281163B2 (de) |
CA (1) | CA2417984C (de) |
DE (1) | DE60142237D1 (de) |
ES (1) | ES2346184T3 (de) |
MX (1) | MXPA03000983A (de) |
WO (1) | WO2002011767A2 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
WO2003009863A1 (en) * | 2001-07-26 | 2003-02-06 | Genset S.A. | Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders |
US20040096446A1 (en) * | 2001-08-17 | 2004-05-20 | Lane Thomas E. | Methods for treating demyelinating diseases |
US20040170602A1 (en) * | 2002-01-04 | 2004-09-02 | Desjarlais John R. | Dominant negative proteins and methods thereof |
EP1576088A4 (de) * | 2002-01-04 | 2006-09-06 | Xencor Inc | Dominant-negative proteine und verfahren dazu |
KR100668538B1 (ko) * | 2002-01-09 | 2007-01-16 | 메다렉스, 인코포레이티드 | Cd30에 대한 인간 모노클로날 항체 |
GB0202769D0 (en) * | 2002-02-06 | 2002-03-27 | Univ Cambridge Tech | Polypeptides methods and means |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
EP1378523A1 (de) * | 2002-07-01 | 2004-01-07 | STEIN, Harald, Prof. Dr. | Anti-cd30-antikörper und deren verwendungen |
US7208579B2 (en) * | 2003-05-30 | 2007-04-24 | The Regents Of The University Of California | IL4 receptor antagonists for horse, dog and cat |
WO2005037314A1 (en) * | 2003-08-20 | 2005-04-28 | Centocor, Inc. | Method for generating antibodies |
DK1667730T3 (da) * | 2003-08-20 | 2013-09-23 | Univ Miami | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom |
WO2005023201A2 (en) * | 2003-09-09 | 2005-03-17 | Medarex, Inc. | Methods for treating rheumatoid arthritis |
DE602004021949D1 (de) * | 2003-09-10 | 2009-08-20 | Hoffmann La Roche | Anti-interleukin-1 rezeptor antikörper und deren verwendung |
AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
MXPA06005941A (es) * | 2003-12-10 | 2006-08-23 | Medarex Inc | Anticuerpos ip-10 y sus usos. |
US7955703B2 (en) * | 2004-07-12 | 2011-06-07 | Lintec Corporation | Silicone rubber based pressure sensitive adhesive sheet |
US20060069436A1 (en) * | 2004-09-30 | 2006-03-30 | Depuy Spine, Inc. | Trial disk implant |
CN101056655A (zh) * | 2004-10-01 | 2007-10-17 | 米德列斯公司 | 治疗cd30阳性淋巴瘤的方法 |
US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
TWI444187B (zh) * | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
BRPI0607203A2 (pt) | 2005-02-18 | 2009-08-25 | Medarex Inc | anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado |
WO2006116246A2 (en) * | 2005-04-25 | 2006-11-02 | Medarex, Inc. | Method of treating cd30 positive lymphomas |
US20070009479A1 (en) * | 2005-06-17 | 2007-01-11 | Aerovance, Inc. | Methods for treating dermatitis using mutant human IL-4 compositions |
CA2621083C (en) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
SG166788A1 (en) * | 2005-10-28 | 2010-12-29 | Centocor Inc | Use of b cell expansion agents in generating antibodies |
WO2007084672A2 (en) * | 2006-01-17 | 2007-07-26 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
CA2635445A1 (en) * | 2006-02-22 | 2007-08-30 | University Of Zurich | Methods for treating autoimmune or demyelinating diseases |
JPWO2007097056A1 (ja) * | 2006-02-23 | 2009-07-09 | イビデン株式会社 | ハニカム構造体および排ガス浄化装置 |
EP2010214A4 (de) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis |
US20100178652A1 (en) * | 2007-01-05 | 2010-07-15 | Litherland Sally A | Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
CN102770455B (zh) | 2009-08-03 | 2017-02-08 | 迈阿密大学 | 用于体内扩增调节性t细胞的方法 |
EP2675467A4 (de) * | 2011-02-18 | 2014-06-25 | Merck Sharp & Dohme | Verwendung von mdl-1-antagonisten zur behandlung von spondylarthropathie |
CN103619880A (zh) | 2011-04-29 | 2014-03-05 | 百时美施贵宝公司 | Ip-10抗体剂量递增方法 |
EP3929208A1 (de) * | 2012-04-27 | 2021-12-29 | Amgen Inc. | Menschliches cd30-ligandantigen bindende proteine |
JP2016504045A (ja) | 2013-01-09 | 2016-02-12 | ザ ユニバーシティー オブ マイアミThe University Of Miami | TL1A−Ig融合タンパク質を用いる制御性T細胞の制御のための組成物及び方法 |
US10556948B2 (en) | 2015-11-30 | 2020-02-11 | Bristol-Myers Squibb Company | IP-10 antibodies and their uses |
AU2019261933A1 (en) * | 2018-04-30 | 2020-12-03 | Cedars-Sinai Medical Center | Methods and systems for selection and treatment of patients with inflammatory diseases |
WO2020096046A1 (ja) * | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連t細胞を標的とした糖代謝異常の予防または治療用ワクチン |
MX2023009621A (es) * | 2021-02-17 | 2023-10-31 | Prometheus Biosciences Inc | Anticuerpos anti-cd30l y usos de estos. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5304635A (en) | 1990-03-12 | 1994-04-19 | University Of Southern California | Antigen specifically expressed on the surface of B cells and Hodgkin's cells |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
EP0672141B1 (de) | 1992-10-23 | 2003-05-14 | Immunex Corporation | Methoden zur herstellung löslicher, oligomerer proteine |
US5670527A (en) * | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
EP1053316A1 (de) * | 1998-02-06 | 2000-11-22 | AbGen GmbH | Nukleinsäuren zur modulation zellulärer aktivierung |
US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
-
2001
- 2001-08-03 US US09/921,667 patent/US6652854B2/en not_active Expired - Lifetime
- 2001-08-06 AU AU2001281163A patent/AU2001281163B2/en not_active Expired
- 2001-08-06 MX MXPA03000983A patent/MXPA03000983A/es active IP Right Grant
- 2001-08-06 ES ES01959628T patent/ES2346184T3/es not_active Expired - Lifetime
- 2001-08-06 CA CA2417984A patent/CA2417984C/en not_active Expired - Lifetime
- 2001-08-06 AT AT01959628T patent/ATE468860T1/de not_active IP Right Cessation
- 2001-08-06 DE DE60142237T patent/DE60142237D1/de not_active Expired - Lifetime
- 2001-08-06 AU AU8116301A patent/AU8116301A/xx active Pending
- 2001-08-06 WO PCT/US2001/024783 patent/WO2002011767A2/en active Search and Examination
- 2001-08-06 JP JP2002517101A patent/JP4938957B2/ja not_active Expired - Lifetime
- 2001-08-06 EP EP01959628A patent/EP1307225B1/de not_active Expired - Lifetime
-
2003
- 2003-08-26 US US10/648,136 patent/US7122183B2/en not_active Expired - Lifetime
-
2006
- 2006-08-18 US US11/506,645 patent/US7273609B2/en not_active Expired - Lifetime
-
2007
- 2007-08-16 US US11/840,136 patent/US20080213259A1/en not_active Abandoned
-
2009
- 2009-11-10 US US12/615,619 patent/US20100071079A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6652854B2 (en) | 2003-11-25 |
MXPA03000983A (es) | 2003-10-06 |
US20080213259A1 (en) | 2008-09-04 |
EP1307225B1 (de) | 2010-05-26 |
WO2002011767A2 (en) | 2002-02-14 |
US7273609B2 (en) | 2007-09-25 |
JP4938957B2 (ja) | 2012-05-23 |
AU2001281163B2 (en) | 2006-03-30 |
JP2005503319A (ja) | 2005-02-03 |
ATE468860T1 (de) | 2010-06-15 |
CA2417984C (en) | 2011-08-02 |
US7122183B2 (en) | 2006-10-17 |
CA2417984A1 (en) | 2002-02-14 |
AU8116301A (en) | 2002-02-18 |
ES2346184T3 (es) | 2010-10-13 |
EP1307225A2 (de) | 2003-05-07 |
US20040076626A1 (en) | 2004-04-22 |
WO2002011767A3 (en) | 2002-12-19 |
US20060280741A1 (en) | 2006-12-14 |
US20020064527A1 (en) | 2002-05-30 |
US20100071079A1 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142237D1 (de) | Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen | |
ATE451930T1 (de) | Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
ATE376835T1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
ATE322290T1 (de) | Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia | |
ATE414556T1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
ATE511655T1 (de) | Verfahren zur auswertung eines myelounterdrückungszustands | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
NO20056073L (no) | Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS) | |
DE60234873D1 (de) | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen | |
ATE345793T1 (de) | Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption | |
ATE497809T1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
ATE395075T1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose | |
HRP20050572A2 (en) | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | |
DE69913548D1 (de) | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen | |
ATE359804T1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten | |
ATE371454T1 (de) | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie | |
ATE353667T1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
ATE256461T1 (de) | Benutzung von comt-inhibitoren als analgetika | |
DE602004004883D1 (de) | Vegf-antagonisten zur behandlung von diabetes | |
ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
DE60122898D1 (de) | Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten | |
ATE486609T1 (de) | Furin-hemmer zur behandlung von fibrose und narbenbildung | |
DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
NO20045343L (no) | Ny kombinasjon for behandling av luftveisforstyrrelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |